Fig. 5.

Depleting circulating CTRP3 using a CTRP3 antibody largely abolished melatonin-mediated protection against diastolic dysfunction. (A) LVEDP after melatonin treatment (n = 5 per group). (B) -dP/dt with melatonin treatment (n = 5 per group). (C) Alterations in the Tau index after melatonin treatment (n = 5 per group). (D) The level of 4-HNE (n = 5 per group). (E-F) The mRNA levels of Sod2 and Gpx (n = 5 per group). All data are expressed as the mean ± SD. Differences were compared by one-way ANOVA followed by Tukey's post hoc test. *P < 0.05.